OneDigital Investment Advisors LLC Sells 6,316 Shares of Abbott Laboratories (NYSE:ABT)

OneDigital Investment Advisors LLC lowered its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 15.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,369 shares of the healthcare product maker's stock after selling 6,316 shares during the period. OneDigital Investment Advisors LLC's holdings in Abbott Laboratories were worth $3,918,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Insight Folios Inc grew its position in Abbott Laboratories by 3.3% during the 3rd quarter. Insight Folios Inc now owns 2,691 shares of the healthcare product maker's stock worth $307,000 after purchasing an additional 87 shares in the last quarter. Boltwood Capital Management boosted its position in shares of Abbott Laboratories by 0.4% in the third quarter. Boltwood Capital Management now owns 21,821 shares of the healthcare product maker's stock worth $2,488,000 after buying an additional 89 shares during the period. Wedge Capital Management L L P NC grew its holdings in shares of Abbott Laboratories by 2.9% during the third quarter. Wedge Capital Management L L P NC now owns 3,153 shares of the healthcare product maker's stock valued at $359,000 after buying an additional 89 shares in the last quarter. Silicon Valley Capital Partners raised its position in Abbott Laboratories by 8.7% during the third quarter. Silicon Valley Capital Partners now owns 1,108 shares of the healthcare product maker's stock valued at $126,000 after buying an additional 89 shares during the period. Finally, Atwood & Palmer Inc. lifted its stake in Abbott Laboratories by 6.5% in the 3rd quarter. Atwood & Palmer Inc. now owns 1,478 shares of the healthcare product maker's stock worth $169,000 after acquiring an additional 90 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Oppenheimer began coverage on Abbott Laboratories in a report on Tuesday, October 8th. They issued an "outperform" rating and a $130.00 target price on the stock. Edward Jones lowered shares of Abbott Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday, July 30th. Raymond James reissued a "buy" rating and set a $129.00 price objective (up previously from $122.00) on shares of Abbott Laboratories in a research report on Monday, October 14th. Mizuho boosted their price target on Abbott Laboratories from $115.00 to $130.00 and gave the company a "neutral" rating in a research note on Thursday, October 17th. Finally, Evercore ISI increased their price target on shares of Abbott Laboratories from $120.00 to $124.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 1st. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $130.07.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, CEO Robert B. Ford sold 141,679 shares of the business's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $116.41, for a total value of $16,492,852.39. Following the transaction, the chief executive officer now directly owns 220,059 shares in the company, valued at $25,617,068.19. The trade was a 39.17 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.10% of the stock is owned by insiders.

Abbott Laboratories Stock Performance

ABT traded up $0.87 on Friday, hitting $115.90. 6,898,605 shares of the stock traded hands, compared to its average volume of 5,701,520. The business has a fifty day moving average price of $115.53 and a two-hundred day moving average price of $109.49. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 52 week low of $97.64 and a 52 week high of $121.64. The firm has a market capitalization of $201.02 billion, a PE ratio of 35.23, a P/E/G ratio of 2.72 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 EPS for the quarter, topping the consensus estimate of $1.20 by $0.01. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. The firm had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $10.55 billion. During the same period last year, the business earned $1.14 earnings per share. Abbott Laboratories's quarterly revenue was up 4.9% compared to the same quarter last year. On average, research analysts predict that Abbott Laboratories will post 4.67 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, November 15th. Investors of record on Tuesday, October 15th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Tuesday, October 15th. This represents a $2.20 annualized dividend and a dividend yield of 1.90%. Abbott Laboratories's dividend payout ratio (DPR) is presently 66.87%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.